Relmada Therapeutics, Inc. (RLMD)Healthcare | Biotechnology | Coral Gables, United States | NasdaqCM
7.48 USD
+0.48
(6.857%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.51 +0.03 (0.401%) ⇧ (April 17, 2026, 7:30 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:24 p.m. EDT
RLMD is a high-risk stock with a negative earnings outlook and a low dividend yield. While there are some bullish analyst ratings and potential for price movement, the fundamentals are weak, and the stock has shown volatility. Short-term traders might consider buying calls if the price moves above the 7.5 strike, but the long-term outlook remains uncertain. Investors should be cautious and monitor earnings reports and market sentiment closely. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.267206 |
| AutoETS | 0.267583 |
| AutoTheta | 0.267814 |
| MSTL | 0.295882 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 134.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.071 |
| Excess Kurtosis | -1.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.095 |
| Market Cap | 784,578,880 |
| Forward P/E | -18.24 |
| Website | https://www.relmada.com |
As of April 11, 2026, 4:24 p.m. EDT: Options speculators are showing mixed signals. The calls show a concentration of open interest (OI) around the 7.5 strike, which is near the current price, indicating some bullish sentiment. However, puts also show OI around the 5.0 strike, which is below the current price, suggesting some bearish sentiment. The high implied volatility (IV) for both calls and puts indicates uncertainty, with traders possibly anticipating significant price movements. The overall options activity suggests a cautious approach, with traders hedging against both upward and downward risks.
| Attribute | Value |
|---|---|
| 52 Week Change | 22.157894 |
| Address1 | 2,222 Ponce de Leon Blvd. |
| Address2 | Floor 3 |
| All Time High | 80.0 |
| All Time Low | 0.24 |
| Ask | 9.16 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,377,940 |
| Average Daily Volume3 Month | 1,698,670 |
| Average Volume | 1,698,670 |
| Average Volume10Days | 1,377,940 |
| Bid | 5.39 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.18 |
| City | Coral Gables |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.48 |
| Current Ratio | 80.214 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.54 |
| Day Low | 7.0513 |
| Debt To Equity | 0.095 |
| Display Name | Relmada Therapeutics |
| Dividend Date | 1,569,801,600 |
| Earnings Call Timestamp End | 1,773,952,200 |
| Earnings Call Timestamp Start | 1,773,952,200 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -13,855,048 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 2.245 |
| Enterprise Value | -31,101,906 |
| Eps Current Year | -0.41 |
| Eps Forward | -0.41 |
| Eps Trailing Twelve Months | -1.45 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.6564 |
| Fifty Day Average Change | 1.8235998 |
| Fifty Day Average Change Percent | 0.32239583 |
| Fifty Two Week Change Percent | 2,215.7893 |
| Fifty Two Week High | 7.94 |
| Fifty Two Week High Change | -0.46000004 |
| Fifty Two Week High Change Percent | -0.05793451 |
| Fifty Two Week Low | 0.268 |
| Fifty Two Week Low Change | 7.212 |
| Fifty Two Week Low Change Percent | 26.910446 |
| Fifty Two Week Range | 0.268 - 7.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,271,000,000 |
| Float Shares | 7,718,550 |
| Forward Eps | -0.41 |
| Forward P E | -18.243902 |
| Free Cashflow | -7,737,662 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07517 |
| Held Percent Institutions | 0.51203 |
| Implied Shares Outstanding | 104,890,224 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,569,801,600 |
| Last Split Factor | 1:4 |
| Long Business Summary | Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. |
| Long Name | Relmada Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 784,578,880 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9070579 |
| Most Recent Quarter | 1,577,750,400 |
| Net Income To Common | -15,005,199 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 784,563,982 |
| Number Of Analyst Opinions | 5 |
| Open | 7.15 |
| Operating Cashflow | -12,092,784 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 786 629 1376 |
| Post Market Change | 0.03000021 |
| Post Market Change Percent | 0.40107232 |
| Post Market Price | 7.51 |
| Post Market Time | 1,776,468,614 |
| Previous Close | 7.0 |
| Price Eps Current Year | -18.243902 |
| Price Hint | 2 |
| Price To Book | 6.3389835 |
| Profit Margins | 0.0 |
| Quick Ratio | 79.924 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | 0.48 |
| Regular Market Change Percent | 6.85714 |
| Regular Market Day High | 7.54 |
| Regular Market Day Low | 7.0513 |
| Regular Market Day Range | 7.0513 - 7.54 |
| Regular Market Open | 7.15 |
| Regular Market Previous Close | 7.0 |
| Regular Market Price | 7.48 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,372,220 |
| Return On Assets | -0.14385 |
| Return On Equity | -0.25625 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 104,888,233 |
| Shares Percent Shares Out | 0.057600003 |
| Shares Short | 6,042,204 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 836,254 |
| Short Name | Relmada Therapeutics, Inc. |
| Short Percent Of Float | 0.058000002 |
| Short Ratio | 1.89 |
| Source Interval | 15 |
| State | FL |
| Symbol | RLMD |
| Target High Price | 19.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 12.8 |
| Target Median Price | 12.0 |
| Total Cash | 116,443,344 |
| Total Cash Per Share | 10.219 |
| Total Debt | 110,247 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.24849 |
| Two Hundred Day Average Change | 4.23151 |
| Two Hundred Day Average Change Percent | 1.3026083 |
| Type Disp | Equity |
| Volume | 2,372,220 |
| Website | https://www.relmada.com |
| Zip | 33,134 |